Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Topical Hydrocortisone in Dry Eye Disease with MGD
NCT05159284Phase 4Recruiting
- Sponsor
- Laboratoires Théa
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of hydrocortisone in dry eye disease (DED), meibomian gland dysfunction (MGD), sponsored by Laboratoires Théa. Started Nov 2021; status: recruiting.
02
Drugs
hydrocortisone
03
Conditions
dry eye disease (DED)meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT05159284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159284.